Skip to main content

Duvelisib Dosage

Medically reviewed by Drugs.com. Last updated on Oct 7, 2024.

Applies to the following strengths: 15 mg; 25 mg

Usual Adult Dose for Chronic Lymphocytic Leukemia

25 mg orally 2 times a day in 28-day cycles until unacceptable toxicity or progressive disease

Comments:

and take the next dose as usual. If a dose is missed by more than 6 hours, wait
and take the next dose at the usual time.
(CMV) infection/reactivation.

Uses: For the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least 2 prior therapies

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.

Dose Adjustments

DOSE MODIFICATION LEVELS:


Nonhematologic Adverse Reactions:
INFECTION:
NON-INFECTIOUS DIARRHEA OR COLITIS:
responsive to antidiarrheal agents, OR asymptomatic (Grade 1) colitis: Maintain current dose; initiate antidiarrheals if needed; monitor weekly until resolved.
unresponsive to antidiarrheals: Withhold therapy until resolved; initiate enteric acting steroids (e.g., budesonide); monitor weekly until resolved; resume at reduced dose.
CUTANEOUS REACTIONS:
PNEUMONITIS WITHOUT SUSPECTED INFECTIOUS CAUSE:
ALT/AST ELEVATION:

Hematologic Adverse Reactions:
NEUTROPENIA:
THROMBOCYTOPENIA:

Dose Modification for Concomitant Use with CYP450 3A4 Inhibitors:

Precautions

US BOXED WARNINGS:
SERIOUS AND/OR FATAL TOXICITIES:
Infections:

Diarrhea/Colitis:
for severe diarrhea or colitis and withhold therapy.
Cutaneous Reactions:
Pneumonitis:

CONTRAINDICATIONS:

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Patient advice:
be fatal; immediately report new or worsening respiratory symptoms such as cough or difficulty breathing.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.